Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 3,663 shares of the business’s stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $21.61, for a total transaction of $79,157.43. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Patrick J. Haley also recently made the following trade(s):
Get Exelixis alerts: On Friday, May 4th, Patrick J. Haley sold 12,549 shares of Exelixis stock. The stock was sold at an average price of $22.38, for a total transaction of $280,846.62. On Monday, May 7th, Patrick J. Haley sold 27,549 shares of Exelixis stock. The stock was sold at an average price of $22.17, for a total transaction of $610,761.33. On Wednesday, February 28th, Patrick J. Haley sold 45,029 shares of Exelixis stock. The stock was sold at an average price of $27.13, for a total transaction of $1,221,636.77.Shares of Exelixis opened at $21.58 on Monday, MarketBeat.com reports. Exelixis, Inc. has a twelve month low of $18.03 and a twelve month high of $32.50. The stock has a market cap of $6.41 billion, a PE ratio of 42.31, a price-to-earnings-growth ratio of 0.55 and a beta of 2.10.
Exelixis (NASDAQ:EXEL) last issued its earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. Exelixis had a net margin of 43.39% and a return on equity of 77.39%. The business had revenue of $120.10 million for the quarter, compared to analyst estimates of $120.25 million. During the same period in the previous year, the business earned $0.12 EPS. The firm’s revenue was up 54.8% on a year-over-year basis. analysts anticipate that Exelixis, Inc. will post 0.86 earnings per share for the current year.
Several research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Exelixis from a “sell” rating to a “strong sell” rating in a report on Friday, May 11th. Cann restated a “buy” rating and set a $40.00 price objective on shares of Exelixis in a report on Thursday. Needham & Company LLC dropped their price objective on shares of Exelixis from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, May 11th. BidaskClub upgraded shares of Exelixis from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 16th. Finally, Zacks Investment Research upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a report on Monday, April 30th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $32.80.
Several institutional investors have recently modified their holdings of EXEL. JPMorgan Chase & Co. boosted its position in shares of Exelixis by 109.4% during the 1st quarter. JPMorgan Chase & Co. now owns 5,035,494 shares of the biotechnology company’s stock valued at $111,537,000 after acquiring an additional 2,630,991 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Exelixis by 426.4% during the 4th quarter. American Century Companies Inc. now owns 1,469,945 shares of the biotechnology company’s stock valued at $44,686,000 after acquiring an additional 1,190,691 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Exelixis by 38.1% during the 4th quarter. Jennison Associates LLC now owns 4,228,761 shares of the biotechnology company’s stock valued at $128,554,000 after acquiring an additional 1,167,758 shares in the last quarter. Smith Asset Management Group LP acquired a new position in Exelixis in the fourth quarter valued at about $26,323,000. Finally, Old Mutual Global Investors UK Ltd. boosted its position in Exelixis by 26.6% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 3,562,369 shares of the biotechnology company’s stock valued at $78,906,000 after buying an additional 747,398 shares in the last quarter. Institutional investors and hedge funds own 77.40% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
No comments:
Post a Comment